Clinical Trial Detail

NCT ID NCT02758717
Title Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Academic and Community Cancer Research United
Indications

Hodgkin's lymphoma

Therapies

Brentuximab vedotin + Nivolumab

Age Groups: senior adult child

No variant requirements are available.